latest news releases from the newsroom
Plasticon International, Inc.
Plasticon Signs Letter of Intent to Acquire Semco Inc., A Pioneer in Leading-edge Surfacing Products
LEXINGTON, Ky., May 25, 2005 (PRIMEZONE) -- Plasticon International Inc. (Pink Sheets:PLNI) today announced that it has signed a letter of intent to acquire Semco, Inc., a Nevada based company that is a pioneer in leading edge resurfacing technology. Pending the completion of due diligence, an acquisition date will be set. The acquisition gives Plasticon a major advantage over its competition because Semco, Inc., which has been profitable for years, is seen as the new industry standard in resurfacing by distributors and construction companies.
FieldTurf to be Installed at Northwestern Football Complex
EVANSTON, Ill., May 25, 2005 (PRIMEZONE) -- Northwestern University has selected FieldTurf as the new artificial turf surface for one of its primary football practice fields at the school's athletic complex. The joint announcement was made today by Northwestern Athletics Director Mark Murphy and FieldTurf CEO John Gilman. The selection of FieldTurf by the Wildcats marks the latest on the lengthy list of major college and NFL installations for FieldTurf, the undisputed leader in the artificial turf industry.
Brodsky & Smith, LLC
Law Offices of Brodsky & Smith, LLC Announces Class Action Lawsuit Against Able Laboratories, Inc. -- ABRX
BALA CYNWYD, Pa., May 25, 2005 (PRIMEZONE) -- Law offices of Brodsky & Smith, LLC today announces that a securities class action lawsuit has been filed on behalf of shareholders who purchased the common stock of Able Laboratories, Inc. (Nasdaq:ABRX) ("Able" or the "Company") between October 31, 2002 and May 18, 2005 inclusive (the "Class Period"). The class action lawsuit was filed in the United States District Court for the District of New Jersey.
Nicodrops Announces the Lawsuit with GlaxoSmithKline Has Been Dismissed
LA MESA, Calif., May 25, 2005 (PRIMEZONE) -- Nicodrops International Inc., a subsidiary of Nicodrops, Inc. (Other OTC: NCDP), developer of the drug-free, herbal dietary supplement smoking alternative lozenge(a), today announced an unfair competition lawsuit filed against it in February 2005 by GlaxoSmithKline Consumer Healthcare (NYSE:GSK) in Federal district court in the Western District of Pennsylvania has been settled to the mutual satisfaction of the parties and has been dismissed.
Wolters Kluwer Successfully Completes Acquisition of De Agostini Professionale and Utet Professionale in Italy
AMSTERDAM, Netherlands, May 25, 2005 (PRIMEZONE) -- Wolters Kluwer Legal, Tax & Regulatory Europe today announced the completion of the acquisition of De Agostini Professionale and Utet Professionale in Italy. De Agostini Professionale and Utet Professionale, with total revenues of approximately Euro 70 million, will further strengthen Wolters Kluwer's position in the Italian information market. Wolters Kluwer reached an agreement on the acquisition of De Agostini Professionale and Utet Professionale in January 2005. This agreement now has been completed, following review and approval by antitrust authorities.
Quest Oil Initiates Phase One Drilling Program for Acadia North Gas Project
ARLINGTON, Texas, May 25, 2005 (PRIMEZONE) -- The Board of Directors of Quest Oil Corporation (OTCBB:QOIL) (www.questoil.com) is pleased to announce that the Company has mobilized its project geologist and survey crew to its Acadia North project, located in Municipal District of Acadia No. 34, Alberta in advance of a 3,000 ft (950 m) drilling program. This drill program marks the Company's first drilling campaign on the Acadia North Project and, when completed, will satisfy the Company's commitment to drill a minimum of one well on or before June 30th, 2005.
New Life Scientific Inc.
New Life Scientific Enters into Agreement to Acquire Pharma Trials International for $1.5 Million
FREEHOLD, N.J., May 25, 2005 (PRIMEZONE) -- New Life Scientific, Inc. (NWLF) (OTCBB:NWLF) announced today that it will acquire Pharma Trials International (PTI) in a $1.5 Million deal that will provide entry and presence in the clinical research field. The transaction calls for NWLF to pay $1.5 Million in common stock. NWLF expects the deal, which is subject to audit, customary closing conditions and regulatory approvals, to close in the third quarter ending September 30, 2005.